Table 4.

Risk of cardiac death event up to 36 months of follow-up among colorectal cancer patients diagnosed from 2005 to 2007 and receiving chemotherapy with or without bevacizumab for newly diagnosed or recurrent disease

	Event no.a	Event rate (per 1000 person-years)	Hazard ratio (HR, 95% CI)b
BEV use	29	7.73	1.63 (0.90, 2.94)
Non-BEV	49	5.15	1.0

^aA total of 6803 patients were included in assessing the risk of cardiac death with BEV. The follow-up times were 3432 and 8658 person-years in the BEV-use and non-BEV use groups, respectively.

^bCox-proportional hazards (PHs) model adjusted for the effects of radiation, surgery, age at chemotherapy initiation, sex, cardiovascular comorbidity and time-dependent use of irinotecan, oxaliplatin, and 5-FU.